for IgGs).50 The extended half-life of peptides can be achieved by
improving their proteolytic stability through chemical
modification, including amide bonds alteration. The choice of
peptide bond mimetic is a compromise between the positive
effect on pharmacokinetics and the potential negative effect on
the activity and specificity of the compounds. In our studies, we
have synthesized a new group of urea-peptidomimetics based on
previous active structures. Obtained results demonstrate that the
substitution of Lys-ɛ-hArg amide bond by urea group and change
19. Keyt, B. A.; Berleau, L. T.; Nguyen, H. V.; Chen, H.; Heinsohn,
H.; Vandeln, R.; Ferrara, N. J. Biol. Chem. 1996, 271, 7788-95.
2
2
0. Soker, S.; Gollamudi-Payne, S.; Fidder, H.; Charmahelli, H.;
Klagsbrun, M. J. Biol. Chem. 1997, 272, 31582-88.
1. Fairbrother, W. J.; Chample, M. A.; Christinger, H. W.; Keyt, B.
A.; Starovasnik, M. A. Structure 1998, 6, 637-48.
22. Parker, M. W.; Xu, P.; Li, X.; Vander Kooi, C. W. J. Biol. Chem.
012, 14, 11082-89.
2
2
3. Teesalu, T.; Sugahara, K. N.; Kotamraju, V. R.; Ruoslahti, E.
Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 16157-62.
2
4. Binétruy-Tournaire, R.; Demangel, C.; Malavaud, B.; Vassy, R.;
Rouyre, S.; Kraemer, M.; Plouët, J.; Derbin, C.; Perret G.; Mazié,
J. C. EMBO J. 2000, 19, 1525-33.
2
3
of hArg side chain for Arg in Lys(hArg)-AA -AA -Arg sequence
eliminated the enzymatic cleavage of peptidomimetic branching.
Simultaneously, VEGF-A165/NRP-1 complex inhibition by urea-
2
5. Perret, G. Y.; Starzec, A.; Hauet, N.; Vergote, J.; Le Pecheur, M.;
Vassy, R.; Léger, G.; Verbeke, K. A.; Bormans, G.; Nicolas, P.;
Verbruggen, A. M.; Moretti, J. L. Nucl. Med. Biol. 2004, 31, 575-
2
3
peptide hybrids depends in major on the residues at the AA -AA
fragment of the molecule, as the substitution of hArg by Arg urea
8
1.
u
unit (Arg ) does not radically affect the affinity for NRP-1. Thus,
26. Starzec, A.; Vassy, R.; Martin, A.; Lecouvey, M.; Di Benedetto,
the designed peptidomimetics, especially compound 3, might be
the sequence for further modifications.
M.; Crépin, M.; Perret, G. Y. Life Sci. 2006, 79, 2370-81.
2
7. von Wronski, M. A.; Raju, N.; Pillai, R.; Bogdan, N. J.; Marinelli,
E. R.; Nanjappan, P.; Ramalingam, K.; Arunachalam, T.; Eaton,
S.; Linder, K.E.; Yan, F.; Pochon, S.; Tweedle, M. F.; Nunn, A. D.
J. Biol. Chem. 2006, 281, 5702-10.
Acknowledgments
2
2
8. Iguchi, S.; Kawasaki, K.; Okamoto, H.; Umezawa, C.; Okada, Y.
Chem. Pharm. Bull. 1999, 47, 423-27.
9. Thomas, N.; Pernot, M.; Vanderesse, R.; Becuwe, P.;
Kamarulzaman, E.; Da Silva, D.; François, A.; Frochot, C.;
Guillemin, F.; Barberi-Heyob, M.. Biochem. Pharmacol. 2010, 80,
This work was financially supported by Grant No.
017/27/N/NZ7/02473 from Narodowe Centrum Nauki (National
Science Centre, Poland). We thank COST Action CA15135:
Multi-target paradigm for innovative ligand identification in the
drug discovery process (MuTaLig), supported by COST
2
2
26-35.
30. Jones, W. C.; Nestor, J. J.; Vigneaud, V. D. J. Am. Chem. Soc.
1973, 95, 5677-79.
3
(
European Cooperation in Science and Technology) for a STSM
1. Lankiewicz, L.; Bowers, C. Y.; Reynolds, G. A.; Labroo, V.;
Cohen, L. A.; Vonhof, S.; Sirén, A. L.; Spatola, A. F. Biochem.
Biophys. Res. Commun. 1992, 184, 359-66.
2. De Zotti, M.; Biondi, B.; Peggion, C.; De Poli, M.; Fathi, H.;
Oancea, S.; Toniolo, C.; Formaggio, F. Beilstein J. Org. Chem.
2012, 8, 1161-71.
3. Tam, A.; Arnold, U.; Soellner, M. B.; Raines, R. T. J. Am. Chem.
Soc. 2007, 129, 12670-71.
4. Nahrwold, M.; Bogner, T.; Eissler, S.; Verma, S.; Sewald, N. Org.
Lett. 2010, 12, 1064-67.
grant that enabled AKP to work for one month at Imagine
Institute in Paris. LC and MS analysis were partially done in
Laboratory of Chemical Synthesis, CePT, Mossakowski Medical
Research Centre, co-financed by EU from the European Regional
Development Fund under the Operational Programme Innovative
Economy, 2007-2013.
3
3
3
3
References and notes
5. Tischler, M.; Nasu, D.; Empting, M.; Schmelz, S.; Heinz, D. W.;
Rottmann, P.; Kolmar, H.; Buntkowsky, G.; Tietze, D.; Avrutina,
O. Angew. Chem. Int. Ed. Engl. 2012, 51, 3708-12.
1
2
.
.
He, Z.; Tessier-Lavigne, M. Cell 1997, 90, 739-51.
Lee, P.; Goishi, K.; Davidson, A. J.; Mannix, R.; Zon, L.;
Klagsbrun, M. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 10470-75.
Staton, C. A.; Kumar, I.; Reed, M. W.; Brown, N. J. J. Pathol.
36. Guichard, G.; Calbo, S.; Muller, S.; Kourilsky, P.; Briand, J. P.;
Abastado, J. P. J. Biol. Chem. 1995, 270, 26057-59.
37. Laurencin, M.; Legrand, B.; Duval, E.; Henry, J.; Baudy-Floc'h,
M.; Zatylny-Gaudin, C.; Bondon, A. J. Med. Chem. 2012, 55,
2025-34.
3
4
.
.
2
007, 212, 237-48.
Mamluk, R.; Gechtman, Z.; Kutcher, M. E.; Gasiunas, N.;
Gallagher, J.; Klagsbrun, M.; J. Biol. Chem. 2002, 277, 24818-25.
Hicklin, D. J.; Ellis, L. M. J. Clin. Oncol. 2005, 23, 1011-27.
Guo, H. F.; Vander Kooi, C. W. J. Biol. Chem. 2015, 290, 29120-
5
6
.
.
38. Tamilarasu, N.; Huq, I.; Rana, T. M. Bioorg. Med. Chem. Lett.
2001, 11, 505-7.
2
6.
Miao, H. Q.; Lee, P.; Lin, H.; Soker, S.; Klagsbrun, M. FASEB J.
000, 14, 2532-39.
39. Tymecka, D.; Puszko, A. K.; Lipiński, P. F.; Fedorczyk, B.;
Wileńska, B.; Sura, K.; Perret G. Y.; Misicka, A. Eur. J. Med.
Chem. 2018, 158, 453-62.
40. Puszko, A. K.; Sosnowski, P.; Tymecka, D.; Raynaud, F.;
Hermine, O.; Lepelletier Y.; Misicka, A. Med. Chem. Comm.
2019, 10, 332-40.
41. Douat-Casassus, C.; Pulka, K.; Claudon, P.; Guichard, G. Org.
Lett. 2012, 14, 3130−33.
42. Pettersen, E. F.; Goddard, T. D.; Huang, C. C; Couch, G. S.;
Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. J. Comput. Chem.
2004, 25, 1605-12.
43. Carpino, L. A.; Han, G. J. Org. Chem. 1972, 37, 3404-9.
44. Carpino, L. A. Am. Chem. Soc. 1993, 115, 4397-98.
45. Liu, W. Q.; Borriello, L.; Allain, B.; Pavoni, S.; Lopez, N.;
Hermine, O.; Garbay, C.; Raynaud, F.; Lepelletier, Y.; Demange,
L. Int. J. Pept. Res. Ther. 2015, 21, 117-24.
46. Allain, B.; Jarray, R.; Borriello, L.; Leforban, B.; Dufour, S.; Liu,
W. Q.; Pamonsinlapatham, P.; Bianco, S.; Larghero, J.; Hadj-
Slimane, R.; Garbay, C.; Raynaud F.; Lepelletier, Y. Cell Signal.
2012, 24, 214-23.
47. Borriello, L.; Montès, M.; Lepelletier, Y.; Leforban, B.; Liu, W.
Q.; Demange, L.; Delhomme, B.; Pavoni, S.; Jarray, R.; Boucher,
J. L.; Dufour, S.; Hermine, O.; Garbay, C.; Hadj-Slimane R.;
Raynaud, F. Cancer Lett. 2014, 349, 120-27.
7
8
9
1
.
.
.
2
Soker, S.; Takashima, S.; Miao, H. Q.; Neufeld G.; Klagsbrun, M.
Cell 1998, 92, 735-45.
Fukasawa, M.; Matsushita, A.; Korc, M. Cancer Biol. Ther. 2007,
6
, 1173-80.
0. Robinson, S. D.; Reynolds, L. E.; Kostourou, V.; Reynolds, A. R.;
da Silva, R. G.; Tavora, B.; Baker, M.; Marshall, J. F.; Hodivala-
Dilke, K. M. J. Biol. Chem. 2009, 284: 33966-81.
1. Valdembri, D.; Caswell, P. T.; Anderson, K. I.; Schwarz, J. P.;
König I.; Astanina, E.; Caccavari, F.; Norman, J. C.; Humphries,
M. J.; Bussolino, F.; Serini, G. PLoS Biol. 2009, 7, e1000025.
2. Grünewald, F. S.; Prota, A. E.; Giese, A.; Ballmer-Hofer, K.
Biochim. Biophys. Acta 2010, 1804, 567-80.
3. Grun, D.; Adhikary, G.; Eckert, R. Oncogene 2016, 35, 4379-87.
4. Handa, A.; Tokunaga, T.; Tsuchida, T.; Lee, Y. H.; Kijima, H.;
Yamazaki, H.; Ueyama, Y.; Fukuda, H.; Nakamura, M. Int J.
Oncol. 2000, 17, 291-95.
5. Kawakami, T.; Tokunaga, T.; Hatanaka, H.; Kijima, H.;
Yamazaki, H.; Abe, Y.; Osamura, Y.; Inoue, H.; Ueyama, Y.;
Nakamura, M. Cancer 2002, 95, 2196-201.
1
1
1
1
1
1
6. Bagri, A.; Tessier-Lavigne, M.; Watts, R. J. Clin. Cancer Res.
2
009, 15, 1860-64.
1
1
7. Prud’homme, G. J.; Glinka, Y. Oncotarget 2012, 9, 921-39.
8. Wild, J. R. L.; Staton, C. A.; Chapple, K.; Corfe, B. M. Int. J. Exp.
Pathol. 2012, 93, 81–103.
48. Pollaro, L.; Heinis C. Med. Chem. Commun. 2010, 1, 319–324.
49. Zorzi, A.; Middendorp S. J.; Wilbs, J.; Deyle, K.; Heinis, C. Nat.
Commun. 2017, 8, 16092.
5
0. Kontermann R. E. Expert. Opin. Biol. Ther. 2016, 16, 903-15.